Norges Bank Makes New Investment in Grifols, S.A. (NASDAQ:GRFS)

Norges Bank acquired a new position in Grifols, S.A. (NASDAQ:GRFS - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 1,940,000 shares of the biotechnology company's stock, valued at approximately $14,434,000. Norges Bank owned about 0.28% of Grifols at the end of the most recent quarter.

Several other large investors have also modified their holdings of GRFS. R Squared Ltd bought a new position in Grifols in the 4th quarter worth approximately $28,000. GAMMA Investing LLC grew its stake in shares of Grifols by 44.5% in the fourth quarter. GAMMA Investing LLC now owns 4,959 shares of the biotechnology company's stock worth $37,000 after acquiring an additional 1,527 shares during the last quarter. Blue Trust Inc. increased its position in Grifols by 254.0% during the fourth quarter. Blue Trust Inc. now owns 6,927 shares of the biotechnology company's stock worth $52,000 after acquiring an additional 4,970 shares during the period. Envestnet Portfolio Solutions Inc. acquired a new position in Grifols during the 4th quarter valued at $77,000. Finally, Raymond James Financial Inc. bought a new stake in Grifols in the 4th quarter valued at $91,000.

Wall Street Analyst Weigh In

Separately, Morgan Stanley started coverage on shares of Grifols in a research report on Wednesday, February 12th. They set an "overweight" rating for the company.

Grifols Stock Performance

Shares of NASDAQ:GRFS traded up $0.24 during trading on Friday, hitting $6.76. 742,316 shares of the stock were exchanged, compared to its average volume of 1,222,811. The company has a market capitalization of $4.65 billion, a price-to-earnings ratio of 5.78 and a beta of 0.41. The company has a debt-to-equity ratio of 1.11, a quick ratio of 0.79 and a current ratio of 2.26. Grifols, S.A. has a 1-year low of $5.79 and a 1-year high of $9.96. The company's fifty day simple moving average is $7.49 and its 200-day simple moving average is $7.88.

Grifols Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease.